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ABSTRACT
Objective To determine the feasibility of a definitive trial 
in primary care of electronic clinical decision support 
(eCDS) for possible oesophago- gastric (O- G) cancer.
Design and setting Feasibility study in 42 general 
practices in two regions of England, cluster randomised 
controlled trial design without blinding, nested qualitative 
and health economic evaluation.
Participants Patients aged 55 years or older, presenting 
to their general practitioner (GP) with symptoms associated 
with O- G cancer. 530 patients (mean age 68 years, 58% 
female) participated.
Intervention Practices randomised 1:1 to usual care 
(control) or to receive a previously piloted eCDS tool for 
suspected cancer (intervention), for use at the discretion 
of the GPs, supported by a theory- based implementation 
package and ongoing support. We conducted 
semistructured interviews with GPs in intervention 
practices. Recruitment lasted 22 months.
Outcomes Patient participation rate, use of eCDS, 
referrals and route to diagnosis, O- G cancer diagnoses; 
acceptability to GPs; cost- effectiveness. Participants 
followed up 6 months after index encounter.
Results From control and intervention practices, we 
screened 3841 and 1303 patients, respectively; 1189 and 
434 were eligible, 392 and 138 consented to participate. 
Ten patients (1.9%) had O- G cancer. eCDS was used 
eight times in total by five unique users. GPs experienced 
interoperability problems between the eCDS tool and 
their clinical system and also found it did not fit with their 
workflow. Unexpected restrictions on software installation 
caused major problems with implementation.
Conclusions The conduct of this study was hampered 
by technical limitations not evident during an earlier pilot 
of the eCDS tool, and by regulatory controls on software 
installation introduced by primary care trusts early in 
the study. This eCDS tool needed to integrate better with 
clinical workflow; even then, its use for suspected cancer 
may be infrequent. Any definitive trial of eCDS for cancer 
diagnosis should only proceed after addressing these 
constraints.
Trial registration number ISRCTN125595588.
BACKGROUND
Recognising the significance of symptoms 
that may indicate an underlying cancer is 
fundamental to clinical practice in primary 
care. However, many patients in primary 
care present with low- risk symptoms, and 
even ‘red flag’ symptoms have a lower posi-
tive predictive value compared with patients 
seen in specialist care.1 Research using data 
from primary care populations has generated 
robust estimates of the risk of cancer in symp-
tomatic patients presenting to general practi-
tioners (GPs),2 3 from which risk assessment 
Strengths and limitations of this study
 ► This feasibility study used an electronic clinical de-
cision support (eCDS) tool for possible oesophago- 
gastric cancer that had been previously developed 
and piloted by Macmillan Cancer Support in collab-
oration with a provider of GP clinical software (TPP).
 ► This was a pragmatic study in primary care, with 
general practitioners (GPs) using the eCDS tool at 
their discretion.
 ► Implementation of the intervention with GPs was 
theory- based, using educational outreach, with on-
going clinical and technical support provided by the 
research team.
 ► Participation in the study was significantly ham-
pered by technical problems relating to the interface 
between the eCDS tool and the GP clinical system 
that had not been reported in an earlier pilot, and 
by restrictions on installation of software on GP sys-
tems introduced without warning by some primary 
care trusts during the implementation phase of the 
study.
 ► For some GPs in the intervention arm of the study, 
the release of updated National Institute for Health 
and Care Excellence guidance on management and 
referral of suspected cancer superseded the need to 
use a decision support tool.
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tools have been developed4 5 and then evaluated.6 In the 
UK, these tools have also been transformed into elec-
tronic clinical decision support (eCDS) formats.7 Their 
implementation has been promoted by the report of the 
Independent Cancer Taskforce for England in 2015,8 
though they remain an underused resource.9
Nevertheless, uncertainty exists about the effectiveness 
of clinical decision support (CDS) for potential cancer 
symptoms and how to best incorporate it into clinical prac-
tice. One systematic review identified the features critical 
to the success of CDS interventions.10 A second review of 
eCDS tools found that they improved practitioner perfor-
mance in 64% of the 97 included studies,11 while a third 
identified prompt fatigue as a strong reason for failure 
of eCDS.12 Most recently, a systematic review of CDS to 
support cancer diagnosis in primary care identified nine 
studies (four randomised controlled trials (RCTs) and 
concluded that the optimal mode of delivery remains 
unclear.13 However, an early study of CDS for suspected 
cancer found that it was more likely to be embedded in 
clinical practice if it supported rather than superseded 
clinical judgment.14 We therefore undertook a study of 
the feasibility of a trial of an eCDS tool for suspected 
cancer. The earlier development of this eCDS had been 
led by Macmillan Cancer Support. We used oesophago- 
gastric (O- G) cancer as our exemplar site.15 We aimed to 
optimise an intervention based on this eCDS tool, estab-
lish its acceptability and collect relevant data to inform 
the design of a subsequent definitive trial. We also sought 
to generate new knowledge on the processes of eCDS in 
primary care and to obtain preliminary evidence on the 
effectiveness, implementation and cost- effectiveness of 
eCDS.
METHODS
This was a multisite feasibility study using a cluster RCT 
design without blinding, supported by the North Wales 
Organisation for Randomised Trials in Health Clinical 
Trials Unit. We used a version of the Macmillan eCDS 
tool based on the Hamilton risk assessment tools,2 for 
the purpose of the study limiting its use to symptoms 
of possible O- G cancer. The tool had been developed 
by Macmillan Cancer Support with TPP (SystmOne) 
and BMJ Informatica and had been distributed in 2013 
as a National Awareness and Early Diagnosis Initiative 
(NAEDI) project to 439 practices in 15 cancer networks 
for a pilot period of 9 months.15 It provided a drop- 
down box with an interactive risk calculator which could 
be opened at the GP’s discretion. Additional symptoms 
could be entered by the GP and a value could be gener-
ated for the risk of a currently undiagnosed O- G cancer.
The protocol for this study has been previously 
published.16 In brief, patients aged 55 years and older, 
presenting to their GP with symptoms associated with 
O- G cancer2 and capable of informed consent were 
recruited from general practices in the North East and 
North Cumbria and the Eastern Local Clinical Research 
Networks. An automated record search tool to identify 
eligible patients for the study was developed in collab-
oration with Information and Computing Services at 
Stockton- on- Tees Primary Care Trust (PCT). This was 
tested and retested to maximise its sensitivity, prior to 
being supplied to participating practices and run on 
a weekly basis. Eligible patients received by post from 
their GP an information pack comprising an invitation 
letter and participant information sheet, together with 
a consent form to permit access to their primary and 
secondary care records for follow- up data. This form was 
returned by post to the research team. Practices (clus-
ters) were randomised by North Wales Organisation for 
Randomised Trials in Health Clinical Trials Unit to receive 
the eCDS tool or to usual care, stratified by the region in 
which they were located. Allocation was balanced within 
region, randomising practices on a 1:1 ratio using block 
sizes of 2. Practices were randomised in pairs to maintain 
allocation concealment.
Implementation of the eCDS tool
Intervention practices received an implementation 
package based on principles of educational outreach.17 
This comprised an initial meeting of 30–60 min on prac-
tice premises between a GP from the research team 
(FMW or GR) and the practice clinicians. The meeting 
included a presentation on the development of the 
eCDS tool, the way that it interfaced with their clinical 
system, how it related to NICE guidance on referral for 
suspected cancer, when and how to use the tool and how 
to interpret the results. The practice manager for each 
practice was visited by a member of the research team 
to support the uploading of the eCDS software and to 
explain the processes for patient searches. The research 
team provided technical support throughout the study. 
GPs had access as necessary to peer- to- peer support 
from clinicians in the research team and received study 
newsletters throughout the study. All practices received 
free access to the Royal College of General Practitioners 
online learning module on cancer diagnosis.
The study was limited to practices operating the TPP 
(SystmOne) clinical system. Practices that had previously 
participated in the NAEDI eCDS initiative were excluded. 
This was a pragmatic study, meaning that the eCDS tool 
could be accessed and the output used at the GP’s discre-
tion. As configured for this study, it did not generate auto-
matic ‘prompts’.
The installation of software on practice computer 
systems for the purpose of research became subject to 
new regulatory controls early in the study. The imple-
mentation of these controls differed between PCTs, but 
the way they were applied in the northeastern PCTs 
resulted in long delays in installation of the eCDS soft-
ware, disrupting the timely activation of the intervention 
arm of the study.
Process and outcome measures
Service- related outcome measures were referral rate by 
referral pathway in each arm of the study, conversion 
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(proportion of referrals with a cancer diagnosis) and 
detection (proportion of OG cancer detected through a 
2- week wait referral) rates. We also sought estimates of 
recruitment and consent rates among those eligible for 
inclusion. Practitioner- related outcomes were frequency 
of use of the eCDS and attitudes to, and role of, the tool 
in clinical practice.
Data collection
BMJ Informatica supplied a version of the tool modified 
to our specification to enable capture of data related to its 
use (symptoms entered and risk score generated) on the 
practice computer network but separate from the GP clin-
ical system and not visible to users. In addition to these 
data, research staff collected individual patient data from 
GP records (online supplemental table 1) 6 months after 
the index consultation, using a previously developed data 
extraction template. Where necessary, hospital gastroen-
terology units were visited to retrieve data on secondary 
care procedures and diagnoses.
Semistructured 1:1 interviews with GPs in intervention 
practices were conducted to identify and gain an under-
standing of the facilitators and constraints influencing 
implementation of eCDS in routine practice.
Sample size and data analysis
The study was designed to provide sufficient process data 
and enough participants with O- G cancer to provide esti-
mates of patient participation rate, use of eCDS and overall 
percentages for binary outcomes. We aimed to recruit a 
minimum of 40 practices with 1:1 randomisation between 
intervention and control arms. Estimates of sample size 
were based on data from the Office of National Statistics, 
Trent Cancer Registry, previous experience of recruit-
ment to primary care trials and pilot searches of primary 
care records, and are fully stated in our protocol paper.16 
We anticipated that over a 16- month period, 2000 eligible 
patients would be asked to participate; 1600 patients 
would be recruited (800 in each arm) and 64 of these (32 
in each arm) would have O- G cancer. The target sample 
size was decided based on estimating feasibility parame-
ters and providing a sufficient amount of process data. 
For example, if the consent rate is 80%, 2000 eligible 
participants are large enough to estimate this with a 95% 
CI of 78% to 82%, and 64 participants with O- G cancer 
are large enough to estimate percentages for binary 
outcomes with 95% CIs no wider than 37%–63% overall 
and no wider than 32%–68% within each arm.
Characteristics of the practices and participating 
patients were summarised using numbers and percent-
ages for categorical variables and means and ranges for 
quantitative variables. Logistic regression was used to 
compare the study arms with respect to referral pathways 
used, use of gastroscopy and cancer diagnoses in crude 
(unadjusted) analyses and analyses adjusted for region 
and practice size. No p values were reported as this was a 
feasibility study.
Health economic methods
An economic model was developed in Microsoft Excel 
2007 to evaluate the cost- effectiveness of using the 
eCDS tool in patients presenting to the GP with symp-
toms potentially representing O- G cancer. The model 
was informed by a conceptual mapping exercise, study 
data and published literature obtained via rapid litera-
ture reviews. Incremental outcomes were modelled using 
probabilistic sensitivity analysis to enable uncertainty 
to be estimated. Detailed costings for installation and 
training were not available. Therefore, a maximum justi-
fiable cost analysis was carried out to estimate what the 
maximum cost of eCDS installation and training could be 
while still allowing it to be cost- effective. A comprehensive 
description of these methods is available.18
Patient and public involvement
A patient reviewed the research proposal prior to submis-
sion for funding and commented on the documents 
included in the patient recruitment pack. Patients also 
participated in the independent study steering committee.
RESULTS
We recruited 42 practices to the study, 21 randomised to 
each arm. Eight practices withdrew over the time course 
(seven intervention and one control). The total recruit-
ment period was from November 2015 to the planned end 
date of December 2017. However, practices commenced 
patient recruitment as their software was installed and 
induction was completed. Therefore, over a median 
patient recruitment period of 17.5 months (range 9–22 
months), we recruited 530 patients in total (table 1 
and figure 1). Two- thirds (68%) of patients identified 
through weekly searches of the clinical and prescribing 
records of participating practices proved ineligible on 
scrutiny of the clinical records. The most frequent reason 
was incorrect identification by a prescription ‘flag’, most 
commonly triggered by prescription of acid- suppressing 
drugs for gastric cytoprotection or reauthorisation of 
long- term medication.
The baseline characteristics of participants in control 
and intervention practices were comparable (table 2). 
Practices in each arm were of comparable mean size; the 
mean number of full- time equivalent GPs in each practice 
was not available.
The number of patients recruited was considerably 
greater in the control arm. This was due to the unforeseen 
delays, previously referred to, at the point of installation 
of the eCDS tool in a number of intervention practices.
The eCDS tool was used on eight unique patients by 
five GPs in five intervention practices over the course of 
the recruitment period. Usage data for three practices 
were lost because the software was removed without prior 
discussion with the research team. No adverse events were 
reported.
Estimates of the intervention effect on the referral 
pathways used, use of gastroscopy and cancer diagnoses 
are reported in table 3.
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Qualitative findings
Nine GPs were interviewed across six practices enrolled 
in the intervention arm (two practices from the northeast 
and four from the eastern area, table 4).
Five of the nine GPs interviewed were female. Five 
had been registered for >20 years. Their practices 
had a spread of patient list sizes and included a small 
urban practice (n<4999) and two large rural practices 
(n>10 000). GPs were interviewed at variable time points 
after their first induction into using the tool; the mean 
interval between induction and first interview was 11 
months (range 2–19 months). Four of the nine GPs 
(three female and one male) were interviewed more 
than once in order to see if their views of eCDS changed 
over time.
Use of eCDS by GPs in participating practices, as 
identified by computer records, was very low and only 
loosely consistent with use claimed during interviews. 
Problems with its use were identified by all GPs inter-
viewed. These related to both access and use of the 
tool, and integrating the tool within clinical practice 
(table 5). The most common challenges with access and 
Table 1 Participant recruitment
Total Intervention Control
Patients identified as potentially eligible by clinical record searching 5144 1303 3841
Patients invited (following GP screening of searches for ineligible patients) 1623 434 1189
Patients consenting to study 530 138 392
Patients with complete follow- up data 527 137 390
Patients with incomplete or no follow- up data 3 1 2
Patients recruited as % of those potentially eligible 10.3% 10.6% 10.2%
Patients recruited as % of those invited 32.7% 31.8% 33.0%
GP, general practitioner.
Figure 1 CONSORT 2010 flow diagram ECASS. CONSORT, Consolidated Standards of Reporting Trials; ECASS, Evaluation of 
a Computer Aid for Assessing Stomach Symptoms.
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use were ‘lack of integration of the software with the 
clinical systems’ (n=7) and ‘slow to access and/or use’ 
(n=6).
When speaking about integrating the tool within clinical 
practice, GPs were frustrated with the apparent mismatch 
between the tool and the clinical context in which they 
practised, where codes were often not used and time was 
always a constraining factor on what could be completed. 
Several had concerns about the accuracy of the data used 
in the tool. Two GPs additionally commented on how the 
tool was not yet embedded in their clinical practice and 
how the new NICE cancer guidelines superseded the tool 
in terms of decision support.
I think the benefits of the other tools are clearer, just 
because of the experience we’ve got with them and 
because they’re accepted by QOF and the local CCG, 
that sort of thing. (GP1)




Female, n (%) 84 (60.9) 225 (57.4)
Age (years), mean (SD) 68.4 (8.7) 68.0 (8.6)
Region, n (%)
  North East 27 (19.6) 227 (57.9)
  Eastern 111 (80.4) 165 (42.1)
Practices N=21 N=21
Region
  North East 11 10
  Eastern 10 11
List size, mean (range) 9682 (1686–15 
447)
10 161 (2371–19 
934)
Table 3 Comparison of outcomes between trial arms
Outcome
Intervention Control Crude comparison Adjusted comparison
% (n/N) % (n/N) OR 95% CI OR 95% CI
Patient was referred. 51.1 (70/137) 48.6 (189/389) 1.11 0.70 to 1.75 1.13 0.73 to 1.76
Patient was referred via standard or 
2WW pathway.
48.9 (67/137) 45.0 (172/382) 1.17 0.73 to 1.88 1.17 0.75 to 1.83
  Patient was referred via standard 
pathway.
26.3 (36/137) 19.1 (73/382) 1.51 0.90 to 2.53 1.28 0.74 to 2.20
  Patient was referred via 2WW 
pathway.
22.6 (31/137) 25.9 (99/382) 0.84 0.42 to 1.66 0.98 0.55 to 1.74
Patient was referred via emergency 
pathway.
0.7 (1/137) 0.8 (3/382) 0.93 0.10 to 8.94 * *
Patient was referred via ‘other’ route. 1.5 (2/137) 1.8 (7/382)
Referred patient had an 
oesophagogastroduodenoscopy 
(OGD).
76.8 (53/69) 75.9 (142/187)
Referred patient was diagnosed with 
O- G cancer.
2.9 (2/69) 3.2 (6/188) 0.91 0.17 to 4.73 0.94 0.17 to 5.30
Patient referred via standard route 
was diagnosed with O- G cancer.
5.7 (2/35) 1.4 (1/73)
Patient referred via 2WW was 
diagnosed with O- G cancer.
0 (0/31) 5 (5/98) * * * *
Patient referred via emergency 
pathway was diagnosed with O- G 
cancer.
0 (0/1) 0 (0/3)
Patient was diagnosed with O- G 
cancer.
1.5 (2/136) 2.1 (8/390) 0.71 0.15 to 3.43 0.86 0.18 to 4.13
Patient diagnosed with O- G cancer 
had been referred.
100 (2/2) 75 (6/8) * * * *
Patient diagnosed with O- G cancer 
had been referred via standard or 
2WW pathway.
100 (2/2) 75 (6/8) * * * *
Model adjusted for practice size and region; referral status not known—four patients (one intervention and three controls); referral 
pathway not known—seven control patients; OGD status not known—three patients (one intervention and two controls); O- G cancer 
status not known—four patients (two interventions and two controls).
*Too few observations to fit the logistic regression model.
n, numerator; N, denominator; O- G, oesophago- gastric; OGD, oesophagogastroduodenoscopy; 2WW, 2- week wait .
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So I think before the new cancer guidelines, I thought 
“Oh yes, that would be good” but since the new can-
cer guidelines, trying to get my head around those, 
most of it, what we have at hospital now, we have, 
probably you know, we have two- week wait proformas. 
So when we're worried about someone, we tend to 
just look on the pro forma to see where they, that’s 
how I work really. (GP7)
On the positive side, many of the GPs welcomed the 
prospect of a tool that could help to communicate risk 
to patients and provide them with clinical grounds for 
referral rather than a clinical ‘hunch’. They particularly 
saw the value of having a tool to use with anxious patients 
who were at low risk, with six GPs thinking they would be 
most likely to use any eCDS tool with patients who were 
overanxious or worried about their cancer risk when they 
themselves saw little reason for concern:
It can be used in a consultation, that’s where it comes 
in handy, just to reassure a patient when my gut in-
stinct is not to be too worried. (GP4).
Table 5 Problems encountered by GPs in use of eCDS
Problems with access and use of eCDS
Lack of integration of the software with the 
clinical systems (n=7)
‘Yes, we had plenty of training. The tool itself wasn't difficult to use it’s just that it 
didn't integrate particularly well with our system’. (GP1)
‘It didn’t really integrate very well with SystmOne – you opened it parallel to 
SystmOne’. (GP8)
Slow to access and/or use (n=6) ‘You had to open up something completely separate to the clinical system that you’re 
working in, and when you’ve got very very limited time that was a negative almost 
pushing you to not using it’. (GP9)
‘I wasn’t very successful with it to be honest because I found that it slowed the 
computer down, I had the perception that it slowed the computer down…’. (GP8)
Software not compatible and crashes 
SystmOne (n=4)
‘We’ve been having quite a lot of issues with it crashing our SystmOne and making 
everything run very slow’. (GP2)
Did not autopopulate (n=3) ‘At the moment, I'm having an issue that the platelets and the demographics are not 
being automatically populated. I suspect that’s just that we've got a version out of 
date. A couple of weeks back, I did ask the manager just to make sure we got the 
most recent version’. (GP6)
Tool is clunky or confusing to use (n=2) ‘But yes,…it is a little bit clunky because it’s not all that obvious that you have to 
press on “Tools” when you get on to it. And then you get to the “Cancer Decision 
Support” icon and then you need to pick the right one, so because we don’t do it 
sort of every day or every week, it could be made slightly easier, I think…It’s also a 
little bit confusing that it asks you for a password but you can actually ignore that, 
but it doesn’t feel very logical, you need to have been talked through it once because 
otherwise it’s difficult to figure it out’. (GP1)
Problems integrating use of the tool with clinical practice
Not enough time within consultations (n=5) ‘They [patients] never come in with one symptom, or one, sort of, issue, so they come 
with a few different things, and whether it’s psychological or not, the tool really, for my 
practice anyway, hasn’t become embedded …. we won’t automatically think, when a 
patient, like out of three problems, one of them is related to a gastric or oesophageal 
cancer, erm, I’m not necessarily going into the tool’. (GP5)
‘No way on this planet any of the GPs under the pressure we were under(…)was 
going to use a separate program’. (GP8)
Did not aid decision making (n=3) ‘So, I put the symptoms in, erm, it just felt, and I documented it in the notes a couple 
of times I think, but I can’t, I couldn’t see what it added- I know it’s for research, but 
I couldn’t see that it added anything for us, it didn’t help me really with any decision- 
making’. (GP9)
Concerns about the accuracy of the data used 
within the tool (n=4)
‘I feel a bit uncomfortable that the tool requires or populates several boxes with old 
information’. (GP1)
‘It had so many different words for very slightly different symptoms and I found that 
a little bit confusing and I’m not sure that anyone would be… how specific everyone 
would be about exactly what kind of symptoms the patient had and also if the patient 
could be particularly specific’. (GP3)
‘We do a lot of our work by free text. We put under headings in free text. So a lot of 
symptoms it uses, it won't pick up because it will be in free text. Sometimes it will be 
there and it will pick up things like the platelets, which is great, and the main thing 
is it’s a gastro- intestinal thing. All the other things that we might put in free text, it 
wouldn't pick up’. (GP7)
eCDS, electronic clinical decision support; GP, general practitioner.
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I mean if you’ve got a patient who is sat there and 
has come in saying “I think I have got, oesophageal 
cancer” or something, then you’re going to be tak-
ing that consultation from a completely different 
tack, you then take the history, you go- you know ra-
tionalise everything with the patient in terms of what 
puts them at risk, what doesn’t put them at risk and 
then using a tool in that circumstance to definitely 
show them that, numerically, you know their risk is 
low. (GP9)
Three GPs thought the main reason for using any 
eCDS tool was to achieve patient benefit: ‘So I think if 
you’ve got a purpose for it and it makes sense to you that 
it’s something that actually will help you look after your 
patients better, we’ll always try to use it’ (GP8). There was 
no record of these GPs having used the study eCDS tool.
Health economic analysis
This analysis predicts the eCDS tool to save 0.028 quality- 
adjusted life years (QALYs) (95% CI −0.014 to 0.071) 
and 0.008 life years (95% CI −0.014 to 0.035) per person 
consulting a GP with symptoms. These benefits come 
primarily from reducing the number of emergency 
referrals—the eCDS is projected to prevent 17 (95% 
CI 3 to 216) emergency referrals per 10 000 individuals 
consulting the GP with symptoms. The maximum cost 
that eCDS installation and training could be and still 
enable the intervention to be cost- effective was estimated 
assuming a willingness to pay threshold of £20 000 per 
QALY. The maximum cost per person consulting the GP 
with symptoms was £569 (95% CI −£265 to £1402), but for 
the eCDS to save costs in the long run, this reduces to £6 
(95% CI −£29 to £53). However, the 95% credible inter-
vals indicate high uncertainty, with a 9.7% probability that 
eCDS produces a QALY loss and an 8.8% probability that 
any cost at all for eCDS installation and training would 
be too high to enable it to be cost- effective at the £20 000 
willingness to pay threshold. A complete report of the 
health economic analysis is available online.18
DISCUSSION
In this feasibility study of eCDS in primary care for 
detecting possible O- G cancer, we found that GPs used 
the tool very infrequently and that poor integration of the 
eCDS tool with the GP workflow was an evident problem. 
Implementation of eCDS in intervention practices was 
seriously disrupted by technical, regulatory and organisa-
tional obstacles that emerged only at the point of instal-
lation on practice computer systems. Any definitive trial 
of eCDS for cancer diagnosis that has clinical endpoints 
will likely require a very large number of participating 
practices for adequate power. It is possible that eCDS 
for suspected O- G cancer in primary care could be cost- 
effective with lower implementation costs, but the data 
generated by this study were insufficient to support such 
a recommendation.
The strengths of this study included its use of a previ-
ously piloted eCDS tool and a theory- based approach to 
implementation. It was a pragmatic study, with GPs in the 
intervention practices free to use the tool as and when 
they thought it necessary, reflecting the way that eCDS 
would be used in daily practice. It addressed a problem 
of identifying patients with upper gastrointestinal symp-
toms who require further evaluation, which is common in 
primary care and places substantial demand on specialist 
services. We successfully optimised the intervention soft-
ware to enable data capture for the purpose of research. 
We obtained valuable insights to inform the design and 
conduct of a definitive trial.19 There were, however, 
several weaknesses. First, two- thirds of patients identified 
as potentially eligible proved not to be so on scrutiny of 
the clinical records. This was despite careful and itera-
tive development of the search strategy with the North 
Tees PCT Information and Computing Service to mini-
mise errors of inclusion. Two study clinicians (GR and 
FW) reviewed the screening process with several practices 
but failed to identify any systematic errors giving rise to 
unwarranted exclusion. While undercoding of diagnoses 
may have reduced the number of eligible patients, any 
consequent prescription should have been identified. 
Second, recruitment of patients to the study was lower 
than anticipated, at 33% of those invited. Third, the 
eCDS tool interfaced poorly with the SystmOne clin-
ical software, a problem not reported in the preceding 
Macmillan NAEDI pilot. This made it slow to use and 
the software developers and TPP were unable to identify 
a remedy. Fourth, new restrictions on the uploading of 
software to GP clinical systems were introduced by PCTs 
early in the study. The way in which these were applied 
in one study region resulted in long delays in activating 
the intervention arm of the study. Fifth, the introduction 
of revised NICE guidelines for management of suspected 
cancer early in the recruitment period was perceived by 
some GPs to supersede the need for an eCDS tool. The 
poor integration of the eCDS tool with the GP workflow 
and rarely perceived need for its use also impacted on 
recruitment of GPs for interview. Lastly, the small sample 
size of the study data, in particular the extremely small 
numbers diagnosed with O- G cancer, resulted in high 
uncertainty in the health economic model.
There are several published reports of eCDS tools for 
cancer diagnosis in primary care.13 Of these, only one has 
been an RCT of an eCDS tool designed to support the 
GP’s assessment at the time of consultation of the risk of 
suspected cancer and to inform their decision on whether 
to refer for specialist assessment. That trial showed that 
a system that integrated a primary care algorithm for 
suspected melanoma and SIAscopy (MoleMate) did not 
improve case selection for referral compared with stan-
dardised use of the Seven Point Checklist, due to the low 
specificity of the diagnostic algorithm.20 Of the remaining 
reports, one was of a laboratory- generated standard text 
prompt for clinical management of patients with a full 
blood count consistent with iron deficiency anaemia,21 
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while two others were of computer algorithms to retro-
spectively identify red flag features in the clinical records 
and flag the record for follow- up or further action.22 23 A 
fourth study was of a computer- based referral template 
intended to improve the information contained in refer-
rals letters.24 Of these, only one demonstrated a signifi-
cant effect, shortening the time to diagnostic evaluation 
for patients with colorectal and prostate, but not lung, 
cancers.23
Use of the eCDS tool in this study was disappointingly 
low. We used an implementation approach, educational 
outreach, which is well established and theoretically 
based. However, interventions to change professional 
behaviour have effect sizes that are modest at best.17 In 
order to avoid the well- recognised problem of prompt 
fatigue, we chose not to include this feature in our eCDS. 
Prompts and the requirement for practitioners to justify 
over- riding them have, however, been identified as one of 
the few features of eCDS associated with improved process 
of care.12 The most recent systematic review of eCDS for 
processes of care draws attention to the complex socio-
technical context in which eCDS is used, reports only a 
small to moderate improvement in targeted processes 
of care and concludes that the predictors of meaningful 
improvement remain undefined.25 Evaluations of eCDS 
for suspected cancer should specifically address the soci-
otechnical context of their use. Tools such as the safety- 
related electronic health record research reporting 
framework (SAFER),26 developed specifically to address 
the multidimensional nature of such interventions, 
should be considered for this purpose.
We identified that this eCDS tool had a role in supporting 
communication around patient care decisions, partic-
ularly for anxious patients considered at low risk by the 
GPs. However, we also found evidence to support the 
three core constructs related to use of these tools that 
have been described by others: trust; the GP’s role as a 
gatekeeper; and the impact on workflow.13 Specifically, 
GPs’ accounts reflected how they did not always trust 
the data used to populate the tool, how difficult it was 
to commit to working with a tool that was not integrated 
into their operating system and how the tool appeared to 
slow their computer processes down. The importance of 
integration of tools for GPs was also a key finding in an 
evaluation of an eCDS tool for melanoma.27
Only one trial of eCDS for suspected cancer in primary 
care has been the subject of a formal health economic 
analysis. The MoleMate eCDS tool was considered to be 
cost- effective, with an incremental cost- effectiveness ratio 
(ICER) of £1896 per QALY gained, but with considerable 
decision uncertainty related to the sensitivity and speci-
ficity of MoleMate when compared with best practice.28 
We consider it possible that eCDS for suspected O- G 
cancer in primary care could be cost- effective if imple-
mentation costs are minimised.
A key finding from this study is how highly susceptible 
implementation of eCDS in primary care is to technical 
and organisational considerations. These include the 
quality of the interface between the eCDS tool and the 
clinical system and the ease of use, one with the other. 
Furthermore, use of eCDS in clinical practice is sensitive 
to how well it integrates with the GP workflow and the 
frequency with which users perceive a need for it. These 
factors will also be relevant to the introduction of eCDS 
in other national healthcare systems. However, some 
challenges specific to the English healthcare system were 
apparent. We found the installation of the research soft-
ware on practice computer systems became subject to 
regulatory controls during the implementation phase of 
the study, and that these differed between PCTs, attracted 
a significant charge in one case and changed over time. 
These administrative restrictions could not have been 
foreseen but seriously disrupted the smooth running of 
the study. Any definitive trial of eCDS for cancer diagnosis 
should not be done without further development of the 
intervention to address the limitations we describe.
In conclusion, to be of practical use in the consultation, 
an eCDS tool for suspected cancer in primary care should 
be technically well integrated with the clinical software 
used by the GP, easily accessed from within that system 
and not impact on its operation. Even then, it is likely to 
be used infrequently and any pragmatic trial of its impact 
on clinical outcomes should be powered accordingly.
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